Previous 10 | Next 10 |
2024-04-18 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Initiative focuses on innovation, partnerships, and advocacy as part of $500 million investment in driving change Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated t...
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9 th , before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 9 th , at 8:30 a.m. ET. Investors will have t...
Powered by digital pathology and AI algorithms, Patholytix Foresight drives speed and quality in toxicologic pathology practices Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI)...
2024-04-09 10:48:26 ET More on Charles River Laboratories Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold' Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript Charles River brokers gene therapy ...
HQ plasmid DNA production to support Phase I trials for gene therapy targeting Bardet-Biedl Syndrome Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeuti...
GMP grade plasmid DNA to serve as a direct therapeutic targeting various indications Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manuf...
2024-04-01 13:41:12 ET BofA analysts published “the most neglected” stocks -- or least crowded -- within each of the 11 sectors of the S&P 500 ( SP500 ).... Read the full article on Seeking Alpha For further details see: These are the most neglected sto...
Researchers highlight translational services to optimize drug development programs Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeti...
ESG progress includes $200M investment in alternative testing methods; achievement of 92% renewable energy usage worldwide Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report , which includes progress an...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
2024-05-09 19:00:06 ET Elizabeth Anderson from Evercore ISI issued a price target of $265.00 for CRL on 2024-05-09 16:15:00. The adjusted price target was set to $265.00. At the time of the announcement, CRL was trading at $230.09. The overall price target consensus is a...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
– First-Quarter Revenue of $1.01 Billion – – First-Quarter GAAP Earnings per Share of $1.30 and Non-GAAP Earnings per Share of $2.27 – – Updates 2024 Guidance – Charles River Laboratories International, Inc. (NYSE: CRL) today rep...